ABSTRACT
BACKGROUND: Community-acquired pneumonia (CAP) requires urgent and specific antimicrobial therapy. However, the causal pathogen is typically unknown at the point when anti-infective therapeutics must be initiated. Physicians synthesize information from diverse data streams to make appropriate decisions. Artificial intelligence (AI) excels at finding complex relationships in large volumes of data. We aimed to evaluate the abilities of experienced physicians and AI to answer this question at patient admission: is it a viral or a bacterial pneumonia? METHODS: We included patients hospitalized for CAP and recorded all data available in the first 3-h period of care (clinical, biological and radiological information). For this proof-of-concept investigation, we decided to study only CAP caused by a singular and identified pathogen. We built a machine learning model prediction using all collected data. Finally, an independent validation set of samples was used to test the pathogen prediction performance of: (i) a panel of three experts and (ii) the AI algorithm. Both were blinded regarding the final microbial diagnosis. Positive likelihood ratio (LR) values > 10 and negative LR values < 0.1 were considered clinically relevant. RESULTS: We included 153 patients with CAP (70.6% men; 62 [51-73] years old; mean SAPSII, 37 [27-47]), 37% had viral pneumonia, 24% had bacterial pneumonia, 20% had a co-infection and 19% had no identified respiratory pathogen. We performed the analysis on 93 patients as co-pathogen and no-pathogen cases were excluded. The discriminant abilities of the AI approach were low to moderate (LR+ = 2.12 for viral and 6.29 for bacterial pneumonia), and the discriminant abilities of the experts were very low to low (LR+ = 3.81 for viral and 1.89 for bacterial pneumonia). CONCLUSION: Neither experts nor an AI algorithm can predict the microbial etiology of CAP within the first hours of hospitalization when there is an urgent need to define the anti-infective therapeutic strategy.
Subject(s)
Coinfection/diagnosis , Community-Acquired Infections/microbiology , Community-Acquired Infections/virology , Pneumonia, Bacterial/diagnosis , Pneumonia, Viral/diagnosis , Aged , Artificial Intelligence , Bacterial Load , Female , Hospitalization , Humans , Male , Middle Aged , Physicians , Pneumonia, Bacterial/microbiology , Pneumonia, Viral/microbiology , Proof of Concept Study , ROC Curve , Retrospective Studies , Time Factors , Viral LoadABSTRACT
BACKGROUND: Currently, the biological diagnosis of Pneumocystis jirovecii pneumonia (PjP infection) usually relies on microbiological investigations in bronchial-alveolar lavage fluid (BALF) by conventional staining methods and/or molecular biology. However, bronchial-alveolar lavage is sometimes complicated to manage, especially in weakened patients. Therefore, alternative clinical samples-easier to collect-are warranted in such specific contexts. OBJECTIVE: Over a four-year period, diagnostic performance of an original method based on combination of quantitative real-time polymerase chain reaction (qPCR) in nasopharyngeal aspirate (NPA) with measurement of ß-(1, 3)-D-glucan antigen (BDG) in serum was prospectively assessed in a single centre. PATIENTS/METHODS: Results were compared with those obtained in BALF through direct staining methods and qPCR. True positives were defined by an independent committee based on clinical, radiological and biological data. Overall, 48 individuals with a definitive diagnosis of PjP infection were included, and 48 controls were selected upon matching for age, sex and underlying disease(s). RESULTS: qPCR results were strongly correlated between BALF and NPA (P < .0001). Altogether, greater diagnostic performance was achieved when establishing the positive cut-off of BDG antigen at 143 pg/mL. In such conditions, sensitivity of the testing based on either positive BDG measurement or positive qPCR in NPA was then calculated at 93.75%, 95% CI [82.37%-98.40%], and specificity at 97.87%, 95% CI [87.66%-100.00%]. CONCLUSIONS: Further validation through multicentre studies is now required, especially for establishing clear cut-offs. However, one could already state that combination of qPCR in the NPA with BDG measurement in serum may be a valuable substitute for BALF examination.
Subject(s)
Nasopharynx/microbiology , Pneumonia, Pneumocystis/diagnosis , beta-Glucans/blood , Aged , Bronchoalveolar Lavage Fluid/microbiology , Female , Humans , Male , Middle Aged , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/microbiology , Real-Time Polymerase Chain Reaction , Sensitivity and SpecificityABSTRACT
BACKGROUND: PCR-based techniques for the diagnosis of community- acquired severe lower respiratory tract infections are becoming the standard of care. However, their relative ability to identify either atypical bacteria or viruses that cause LRTI from clinical samples from various sources is yet to be determined. OBJECTIVES AND STUDY DESIGN: The aim of our study was to compare the diagnostic yield of nasopharyngeal aspirates with that of pulmonary samples for the etiological diagnosis of severe acute lower respiratory tract infections by multiplex PCR. Patients were adults with community-acquired pneumonia or acute exacerbation of chronic obstructive pulmonary disease. RESULTS: We obtained concordant results for 81 (79%) of the 103 pairs of samples. In 14 of the 22 discordant results, more pathogens were evidenced in the lower respiratory tract samples. CONCLUSIONS: Pulmonary samples had a similar diagnostic sensitivity for virus detection by multiplex PCR as nasopharyngeal aspirates. In contrast, in our study, the diagnostic efficacy of pulmonary samples for Legionella pneumophila over simple aspirates was clearly superior.
Subject(s)
Bacteria/isolation & purification , Community-Acquired Infections/diagnosis , Multiplex Polymerase Chain Reaction , Respiratory Tract Infections/diagnosis , Viruses/isolation & purification , Adult , Aged , Aged, 80 and over , Community-Acquired Infections/microbiology , Community-Acquired Infections/virology , Female , Humans , Male , Middle Aged , Nasopharynx , Pneumonia/diagnosis , Pneumonia/microbiology , Pneumonia/virology , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/virology , Sensitivity and Specificity , Suction , Young AdultABSTRACT
Current influenza vaccination strategy is based on limited analyses of circulating strains and has some drawbacks, as illustrated during the 2014-2015 season with the circulation of A(H3N2) viruses belonging to divergent genetic subgroups. We reasoned that these strains, poorly neutralized in vitro, may have been associated with vaccination failure and more severe diseases. We conducted a study on a continuous series of 249 confirmed influenza infections. Incidence was three fold greater than in the previous three years. Most isolates were A(H3N2) viruses (78%) and clustered in subgroups 3C.2a (57%) and 3C.3b (43%). We identified 23 non-synonymous mutations that had already been identified during previous seasons at low frequencies, except mutation Q197H, present in 26% of 3C.3b isolates. We identified lung disorder, tobacco smoking and A(H1N1)pdm09 infection as risk factor of severe influenza disease. In contrast, young age (< 5 years), A(H3N2) infection and initial admission to an emergency department were associated with a better outcome of influenza infection.
Subject(s)
Hospitalization/statistics & numerical data , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza Vaccines/adverse effects , Influenza, Human/drug therapy , Severity of Illness Index , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Female , France/epidemiology , Humans , Influenza A Virus, H1N1 Subtype/genetics , Influenza A Virus, H3N2 Subtype/genetics , Influenza, Human/epidemiology , Influenza, Human/virology , Lung Diseases/complications , Male , Middle Aged , Phylogeny , Retrospective Studies , Risk Factors , Tobacco Smoking/adverse effects , Treatment Failure , Vaccination , Young AdultABSTRACT
Hepatitis C virus (HCV) evolves rapidly in a single host and circulates as a quasispecies wich is a complex mixture of genetically distinct virus's but closely related namely variants. To identify intra-individual diversity and investigate their functional properties in vitro, it is necessary to define their quasispecies composition and isolate the HCV variants. This is possible using single genome amplification (SGA). This technique, based on serially diluted cDNA to amplify a single cDNA molecule (clonal amplicon), has already been used to determine individual HCV diversity. In these studies, positive PCR reactions from SGA were directly sequenced using Sanger technology. The detection of non-clonal amplicons is necessary for excluding them to facilitate further functional analysis. Here, we compared Next Generation Sequencing (NGS) with De Novo assembly and Sanger sequencing for their ability to distinguish clonal and non-clonal amplicons after SGA on one plasma specimen. All amplicons (n = 42) classified as clonal by NGS were also classified as clonal by Sanger sequencing. No double peaks were seen on electropherograms for non-clonal amplicons with position-specific nucleotide variation below 15% by NGS. Altogether, NGS circumvented many of the difficulties encountered when using Sanger sequencing after SGA and is an appropriate tool to reliability select clonal amplicons for further functional studies.
Subject(s)
Hepacivirus/genetics , High-Throughput Nucleotide Sequencing/methods , Female , Genetic Variation/genetics , Genome, Viral/genetics , Genomics/methods , Glycoproteins/genetics , Humans , Polymerase Chain Reaction , Reproducibility of Results , Sequence Analysis, DNA/methodsABSTRACT
Reports of carbapenemase-producing Enterobacteriaceae in Africa remain rare and assess mostly blaOXA-48-producing isolates from Mediterranean countries and South Africa. We identified blaNDM-7-producing Enterobacteriaceae in Gabon in 2016. The isolates contained blaNDM-7 IncX3 plasmids that were unusual and similar to the one described in a colistin-resistant Klebsiella pneumoniae SZ04 isolate from China.
Subject(s)
Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/microbiology , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/genetics , beta-Lactamases/genetics , Anti-Bacterial Agents , Communicable Diseases, Emerging/history , Enterobacteriaceae/classification , Enterobacteriaceae Infections/history , Gabon/epidemiology , History, 21st Century , Humans , Microbial Sensitivity Tests , Multilocus Sequence Typing , Phylogeny , Prevalence , beta-Lactamases/biosynthesisABSTRACT
BACKGROUND: Cytomegalovirus (CMV) has a role in chronic rejection and graft loss in kidney transplant (KTx) and lung transplant (LTx) recipients. In addition, donor CMV seropositivity is an independent risk factor for renal graft loss. The anti-CMV response might modulate this risk. Expression of programmed cell death 1 (PD-1), a receptor involved in viral-specific T-cell exhaustion, is influenced by a single nucleotide polymorphism called PD-1.3 (wild-type allele G, variant allele A). METHODS: We performed a retrospective study to assess the impact of PD-1.3 on graft outcome in donor CMV seropositive (D+) and donor CMV seronegative (D-) KTx and LTx. We also performed a case-control study to evaluate the anti-CMVpp65 response according to genotype. RESULTS: PD-1.3 was determined in 1,119 KTx and 181 LTx. In 481 D+ KTx, A allele carriers (24%) experienced significantly less graft failure compared with GG carriers (p = 0.001). Multivariate analysis showed that this association was independent of donor and recipient age, acute rejection episodes, and number of human leukocyte antigen mismatches (hazard ratio, 0.381; 95% confidence interval, 0.209-0.696; p = 0.002). Analysis in 85 D+ LTx showed similar results: A allele carriers had better survival (hazard ratio, 0.302; 95% confidence interval, 0.128-0.716; p = 0.006) and greater 6-month forced expiratory volume (71% ± 17% vs 54% ± 16%, p = 0.001). In D- recipients, PD-1.3 did not affect KTx or LTx outcome. Finally, AA recipients had a stronger anti-CMVpp65 T-cell response than matched GG recipients (p = 0.003). CONCLUSIONS: The A variant allele in PD-1.3 single nucleotide polymorphism improved graft survival in kidney and lung transplant recipients receiving grafts from CMV-positive donors.
Subject(s)
B7-H1 Antigen/genetics , Cytomegalovirus Infections/diagnosis , Cytomegalovirus/isolation & purification , Graft Rejection/genetics , Polymorphism, Genetic , Adult , Case-Control Studies , Confidence Intervals , Female , Graft Survival , Humans , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Lung Transplantation/adverse effects , Lung Transplantation/methods , Male , Middle Aged , Prognosis , Proportional Hazards Models , Retrospective Studies , Seroepidemiologic Studies , Tissue Donors , Transplant RecipientsABSTRACT
We isolated from aerobic and anaerobic blood culture bottles from a febrile patient, a Helicobacter-like Gram negative, rod-shaped bacterium that MALDI-TOF MS failed to identify. Blood agar cultures incubated in a microaerobic atmosphere revealed a motile Gram negative rod, which was oxidase, catalase, nitrate reductase, esterase, and alkaline phosphatase positive. It grew at 42°C with no detectable urease activity. Antimicrobial susceptibility testing showed that the organism was susceptible to beta-lactams, gentamicin, erythromycin, and tetracycline but resistant to ciprofloxacin. Electronic microscopy analysis revealed a 3 × 0.5 µm curved rod bacterium harboring two sheathed amphitrichous flagella. Whole genome sequencing revealed a genome 1,708,265 base-pairs long with a GC content of 37.80% and a total of 1,697 coding sequences. The genomic analyses using the nucleotide sequences of the 16S rRNA gene, hsp60 and gyrB genes, as well as the GyrA protein sequence, and the results of Average Nucleotide Identity and in silico DNA-DNA hybridization suggest evidence for a novel Helicobacter species close to Helicobacter equorum and belonging to the group of enterohepatic Helicobacter species. As soon as the particular peptide mass fingerprint of this pathogen is added to the spectral databases, MALDI-TOF MS technology will improve its identification from clinical specimens, especially in case of "sterile infection". We propose to associate the present strain with the Latin name of the place of isolation; Caesarodunum (Tours, France) and suggest "Helicobacter caesarodunensis" for further description of this new bacterium.
Subject(s)
Bacteriuria/diagnosis , Escherichia coli Infections/diagnosis , Escherichia coli/enzymology , Escherichia coli/isolation & purification , beta-Lactamases/genetics , Aged , Anti-Bacterial Agents/pharmacology , Bacteriuria/microbiology , DNA Transposable Elements , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Escherichia coli/genetics , Escherichia coli Infections/microbiology , Female , France , Gene Order , Humans , Microbial Sensitivity Tests , Sequence Analysis, DNASubject(s)
Black People , Infectious Disease Transmission, Vertical , Trypanosomiasis/epidemiology , Trypanosomiasis/transmission , Female , France/epidemiology , France/ethnology , Humans , Infant , Male , Mothers , Trypanosomiasis/diagnosis , Trypanosomiasis/parasitology , Trypanosomiasis, African/epidemiology , Trypanosomiasis, African/parasitology , Trypanosomiasis, African/transmissionABSTRACT
BACKGROUND/OBJECTIVES: Guidelines for optimized HCV screening are urgently required in Africa, especially for patients infected with HIV, who sometimes show false positive or false negative reactivity in anti-HCV antibody assays. Here, we assessed the usefulness of a fourth-generation HCV Ag-Ab ELISA for the identification of active HCV infection in HIV-positive patients. METHODS: This cross-sectional study was conducted between 03/2010 and 01/2013 and included 762 Gabonese HIV-positive adult patients. The results of ELISA (Monolisa HCV Ag-Ab ULTRA, Bio-Rad) were compared with those obtained by RT-PCR (gold standard). The optimal ELISA signal-to-cutoff (S/CO) ratio to identify patients with active hepatitis C (positive HCV RNA) was determined. Specimens were further tested by the INNO-LIA HCV Score assay (Innogenetics) and the Architect HCV Ag kit (Abbott) to define the best diagnostic strategy. RESULTS: Sixty-seven patients tested positive for HCV (S/CO ratio ≥ 1) by ELISA. Of these, 47 (70.1%) tested positive for HCV RNA. The optimal S/CO associated with active HCV infection was 1.7. At this threshold, the sensitivity of ELISA was 97.9% (95% confidence interval (CI) 90.0-99.9%), its specificity was 91.3% (95% CI 85.0-95.5%), and HCV seroprevalence rate was 7.3% (56/762) (95% CI 5.6-9.4%). Among 57 HCV-seropositive patients with available INNO-LIA results, false reactivity was identified in 14 (24.6%), resolved HCV infection in two (3.5%), possible acute HCV infections in nine (15.8%) and likely chronic HCV infections in 32 (56.1%) patients. HCV core Ag was undetectable in 14/15 (93.3%) specimens that tested negative for HCV RNA whereas it was quantified in 34 (out of 39, 87.2%) samples that tested positive for HCV RNA. CONCLUSIONS: Our study provides comprehensive guidance for HCV testing in Gabon, and will help greatly clinicians to improve case definitions for both the notification and surveillance of HCV in patients co-infected with HIV.
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , HIV Infections/complications , Hepatitis C/complications , Hepatitis C/diagnosis , Adolescent , Adult , Cross-Sectional Studies , False Positive Reactions , Female , Gabon , Hepatitis C/immunology , Hepatitis C Antibodies/immunology , Hepatitis C Antigens/immunology , Humans , Male , Middle Aged , Young AdultABSTRACT
We prospectively assessed the ability of FilmArray® device to identify fungal species involved in bloodstream infections. It succeeded in identifying 85.7% of isolates. The automated readout of results enabled the rapid initiation of appropriate antifungal therapy. Thus, FilmArray® appeared as a reliable alternative diagnostic method for the most common yeast-like species.
Subject(s)
Blood/microbiology , Fungemia/diagnosis , Microbiological Techniques/methods , Molecular Diagnostic Techniques/methods , Yeasts/classification , Yeasts/isolation & purification , Adult , Aged , Aged, 80 and over , Child , Female , Fungemia/microbiology , Humans , Infant , Male , Middle Aged , Prospective Studies , Sensitivity and SpecificityABSTRACT
Hepatitis C virus (HCV) remains a challenging public health problem worldwide. The identification of viral variants establishing de novo infections and definition of the phenotypic requirements for transmission would facilitate the design of preventive strategies. We explored the transmission of HCV variants in three cases of acute hepatitis following needlestick accidents. We used single-genome amplification of glycoprotein E1E2 gene sequences to map the genetic bottleneck upon transmission accurately. We found that infection was likely established by a single variant in two cases and six variants in the third case. Studies of donor samples showed that the transmitted variant E1E2 amino acid sequences were identical or closely related to those of variants from the donor virus populations. The transmitted variants harbored a common signature site at position 394, within hypervariable region 1 of E2, together with additional signature amino acids specific to each transmission pair. Surprisingly, these E1E2 variants conferred no greater capacity for entry than the E1E2 derived from nontransmitted variants in lentiviral pseudoparticle assays. Mutants escaping the antibodies of donor sera did not predominate among the transmitted variants either. The fitness parameters affecting the selective outgrowth of HCV variants after transmission in an immunocompetent host may thus be more complex than those suggested by mouse models. Human antibodies directed against HCV envelope effectively cross-neutralized the lentiviral particles bearing E1E2 derived from transmitted variants. These findings provide insight into the molecular mechanisms underlying HCV transmission and suggest that viral entry is a potential target for the prevention of HCV infection.
Subject(s)
Hepacivirus/metabolism , Hepatitis C/transmission , Hepatitis C/virology , Viral Envelope Proteins/metabolism , Amino Acid Sequence , Animals , Female , Hepacivirus/chemistry , Hepacivirus/classification , Hepacivirus/genetics , Humans , Male , Mice , Molecular Sequence Data , Phylogeny , Sequence Alignment , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/geneticsABSTRACT
BACKGROUND: Despite implementation of universal infant hepatitis B (HB) vaccination, mother-to-child transmission (MTCT) of hepatitis B virus (HBV) still occurs. Limited data are available on the residual MTCT of HBV in human immunodeficiency virus (HIV)-HBV co-infected women. OBJECTIVES: We assessed the prevalence of HBV infection among HIV-infected pregnant women and the rate of residual MTCT of HBV from HIV-HBV co-infected women and analyzed the viral determinants in mothers and their HBV-infected children. STUDY DESIGN: HIV-1 infected pregnant women enrolled in two nationwide perinatal HIV prevention trials in Thailand were screened for HB surface antigen (HBsAg) and tested for HBeAg and HBV DNA load. Infants born to HBsAg-positive women had HBsAg and HBV DNA tested at 4-6 months. HBV diversity within each HBV-infected mother-infant pair was analyzed by direct sequencing of amplified HBsAg-encoding gene and cloning of amplified products. RESULTS: Among 3312 HIV-1 infected pregnant women, 245 (7.4%) were HBsAg-positive, of whom 125 were HBeAg-positive. Of 230 evaluable infants born to HBsAg-positive women, 11 (4.8%) were found HBsAg and HBV DNA positive at 4-6 months; 8 were born to HBeAg-positive mothers. HBV genetic analysis was performed in 9 mother-infant pairs and showed that 5 infants were infected with maternal HBV variants harboring mutations within the HBsAg "a" determinant, and four were infected with wild-type HBV present in highly viremic mothers. CONCLUSIONS: HBV-MTCT still occurs when women have high HBV DNA load and/or are infected with HBV variants. Additional interventions targeting highly viremic women are thus needed to reduce further HBV-MTCT.
Subject(s)
HIV Infections/complications , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/transmission , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/virology , Adult , DNA, Viral/blood , Female , HIV Infections/epidemiology , Hepatitis B Surface Antigens/blood , Hepatitis B e Antigens/blood , Hepatitis B, Chronic/epidemiology , Humans , Infant , Infant, Newborn , Pregnancy , Prevalence , Thailand/epidemiology , Young AdultABSTRACT
After HCV infection, the association between the humoral response and viral sequence evolution remains unclear. We investigated the mechanisms leading to early HCV clearance and spontaneous recovery in two patients. The early evolution of the HCV envelope glycoproteins, and the infectivity spectrum of variants were explored using retroviral pseudoparticles bearing HCV envelopes. Ability of the autologous neutralizing response to control these variants was analyzed. For the first case, the maximum neutralizing activity was for serum collected between two and three months post ALT peak, this activity was still detectable after 30 months. For the second case, autologous neutralizing activity against the variant isolated at the ALT peak was detected in every serum collected between 4 days and 13 months after. The neutralizing response was sustained beyond the time at which the virus was cleared. This raise interesting questions about the role of such antibodies in case of re-exposure.
Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Hepatitis C/immunology , Adult , Evolution, Molecular , Female , Humans , Male , Middle Aged , Molecular Sequence Data , RNA, Viral/genetics , Sequence Analysis, DNA , Time Factors , Viral Envelope Proteins/geneticsABSTRACT
BACKGROUND: Prevalence and risk factors for isolated antibody to hepatitis B core antigen (anti-HBc) and occult hepatitis B virus (HBV) infection are not well known in human immunodeficiency virus type 1 (HIV-1)-infected pregnant women. It is unclear if women with occult infections are at risk of transmitting HBV to their infants. METHODS: HIV-1-infected and HBV surface antigen (HBsAg)-negative pregnant women were tested for antibody to HBsAg (anti-HBs) and anti-HBc using enzyme immunoassay. Women with isolated anti-HBc were assessed for occult HBV infection, defined as HBV DNA levels >15 IU/mL, using the Abbott RealTime HBV DNA assay. Infants born to women with isolated anti-HBc and detectable HBV DNA were tested at 4 months of age for HBV DNA. Logistic regression analysis was used to identify factors associated with isolated anti-HBc and occult HBV infection. RESULTS: Among 1812 HIV-infected pregnant women, 1682 were HBsAg negative. Fourteen percent (95% confidence interval [CI], 12%-15%) of HBsAg-negative women had an isolated anti-HBc that was independently associated with low CD4 count, age >35 years, birth in northern Thailand, and positive anti-hepatitis C virus serology. Occult HBV infection was identified in 24% (95% CI, 18%-30%) of women with isolated anti-HBc, representing 2.6% (95% CI, 1.9%-3.5%) of HIV-1-infected pregnant women, and was inversely associated with HIV RNA levels. None of the women with isolated anti-HBc and occult HBV infection transmitted HBV to their infants. CONCLUSIONS: HIV-1-infected pregnant women with isolated anti-HBc and occult HBV infection have very low HBV DNA levels and are thus at very low risk to transmit HBV to their infants.
Subject(s)
HIV-1/isolation & purification , Hepatitis B Antibodies/blood , Hepatitis B Core Antigens/immunology , Hepatitis B, Chronic/virology , Pregnancy Complications, Infectious/virology , Adult , Analysis of Variance , Cohort Studies , Female , HIV Infections/epidemiology , HIV Infections/immunology , HIV Infections/virology , Hepatitis B Surface Antigens/immunology , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/immunology , Humans , Infant , Infectious Disease Transmission, Vertical/statistics & numerical data , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/immunology , Prevalence , Risk Factors , Thailand/epidemiology , Viral LoadABSTRACT
Care-related infections are a major public health concern. Their transmission can be associated with environmental factors. This study looks at air contamination around 45 patients colonized with multidrug-resistant organisms (MDROs). We found that 30 hospital rooms (67%) were contaminated with MDRO species and 10 rooms (22%) were contaminated with at least 1 MDRO.
Subject(s)
Air Microbiology , Drug Resistance, Multiple, Bacterial , Enterococcus faecium/isolation & purification , Gram-Negative Bacteria/isolation & purification , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Patients' Rooms , Case-Control Studies , Colony Count, Microbial , Enterococcus faecium/physiology , Gram-Negative Bacteria/physiology , Gram-Negative Bacterial Infections/transmission , Gram-Positive Bacterial Infections/transmission , Humans , Methicillin-Resistant Staphylococcus aureus/physiology , Prospective StudiesABSTRACT
BACKGROUND: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. METHODOLOGY/PRINCIPAL FINDING: HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030) and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg). At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log(10) IU/mL and 4.47 log(10) copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24%) lost HBsAg and 7 of 8 (88%) HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months). HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L. CONCLUSIONS: All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3TC.
Subject(s)
Antiretroviral Therapy, Highly Active , HIV Infections/drug therapy , Hepatitis B/drug therapy , Lamivudine/therapeutic use , Adult , Alanine Transaminase/blood , CD4-Positive T-Lymphocytes , Drug Resistance, Viral/genetics , Female , HIV Infections/complications , Hepatitis B/complications , Hepatitis B virus/physiology , Humans , Lamivudine/pharmacology , Male , Mutation , Thailand , Viral Load , Virus Replication/drug effectsABSTRACT
BACKGROUND: This study was conducted to estimate the prevalence and risk factors of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infection among women consulting for abortion and to discuss screening for these pathogens in this population. STUDY DESIGN: Systematic CT/NG screening using real-time polymerase chain reaction was performed on cervical samples from 421 women who consulted for abortion over a 6-month period. RESULTS: Among the 421 women included, 13 had symptoms of gynecological infection, and 408 were asymptomatic. Only one of the symptomatic women was infected with CT (7.7%), and none of the women were infected with NG. Among the asymptomatic women, 40 were CT infected (9.8%), and three were NG infected. The overall prevalence was 9.7% for CT infection and 0.7% for NG infection. CONCLUSIONS: This population had a high prevalence of CT infection and a low prevalence of NG infection. Most infections were asymptomatic, which could justify systematic simultaneous screening for these two pathogens.
Subject(s)
Abortion, Induced , Chlamydia Infections/diagnosis , Chlamydia trachomatis , Gonorrhea/diagnosis , Adult , Cervix Uteri/microbiology , Chlamydia Infections/epidemiology , Female , Gonorrhea/epidemiology , Humans , Neisseria gonorrhoeae , Pregnancy , Pregnancy Complications, Infectious , Preoperative Care , Prospective Studies , Real-Time Polymerase Chain ReactionABSTRACT
Herpes simplex virus (HSV) infection is rarely considered in the differential diagnosis of severe acute hepatitis and disseminated infection in immunocompetent adults. A case of disseminated HSV-1 infection in an 82-year-old woman initially presenting with neurological problems, signs of meningitis and prominent hepatitis was investigated. Initial diagnosis, monitoring, and follow-up were based on the application of molecular methods to cerebrospinal fluid, serum, and liver tissue samples from this patient. Following an initial full recovery, the patient presented delayed intracerebral haemorrhage and diffuse arthralgia. This atypical case, with delayed secondary progression, highlights the wide range of clinical features of HSV infection and the benefits of monitoring viral load by quantitative real-time polymerase chain reaction (PCR) during patient management.